InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,303.27
(
0.12%
)
US TECH 100
18,062.00
(
-0.10%
)
Dow Jones
40,003.59
(
0.34%
)
Brent Oil
83.76
(
0.00%
)
Bitcoin
67,174.92
(
0.35%
)
Post# of 251859
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119662
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 210166

Monday, 03/27/2017 10:23:54 AM

Monday, March 27, 2017 10:23:54 AM

Post# of 251859

AZN—Many people are not aware that EGFR-driven lung cancer is an order of magnitude more prevalent in China than in the US, so this is very significant.

Oldtimers should know this from the history of Iressa (the drug that Tagrisso will supersede).

AZN is (as best i can tell) already the biggest multinational in the Chinese prescription drug market, and is 50:50 partner with Fibrogen for roxadustat in China.

AZN claims to be the #1 multinational drug company in China and the overall #2 drug company in China.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up